| Over a month ago | ||||
Virtual Meetings to be… Virtual Meetings to be held on March 17-18 hosted by Truist. | ||||
Virtual Meetings to be… Virtual Meetings to be held on March 17-18 hosted by Truist. | ||||
Virtual Meetings to be… Virtual Meetings to be held on March 17-18 hosted by Truist. | ||||
"While COVID-19… "While COVID-19 continues to pose a risk of uncertainty to the Company's operating results, Aziyo expects total net sales for the full year 2021 to range between $50 million and $52 million, representing growth of approximately 17% to 22% compared to total net sales for the full year 2020," said the company in a statement.. | ||||
Reports Q4 revenue… Reports Q4 revenue $12.5M, consensus $11.64M. "Despite the unprecedented landscape of 2020, the Aziyo team made meaningful progress throughout the year, resulting in robust top line revenue growth for our core products and continued gross margin improvement. We were also successful in driving forward our strategic priorities, including the advancement of our orthobiologic products and CanGaroo platform, increased clinical data, and the expansion of key partnerships that we believe will enable us to broaden our reach in the regenerative medicine markets. We have also begun to see the benefit of our contract manufacturing business, which leverages our operational capabilities and contributes positively to our bottom line," said Ron Lloyd, Chief Executive Officer. "We look forward to building on this traction, as I am encouraged that we are taking the steps necessary to foster continued success during 2021 and beyond." | ||||
Aziyo Biologics announced… Aziyo Biologics announced today the first patient enrolled in the HEAL Study, investigating the biologic and clinical effects of device envelopes which are placed around cardiovascular implantable electronic devices, "CIEDs" at the time of implantation surgery. The study focuses on identifying characteristics of soft tissue healing surrounding the CIED implant using tissue biopsies taken at the time of the change-out/revision procedure for patients treated with or without an envelope at the time of device implantation. Additional visual, structural and clinical assessments will provide insight into the clinical impact that the implant pocket healing has on the subsequent surgical procedure challenges and risks. Additional analyses will explore comparison between cohorts of documented clinical outcomes and complications since the most recent CIED procedure through the current change-out/revision procedure. |
| Over a quarter ago | ||||
Piper Sandler analyst… Piper Sandler analyst Matt O'Brien keeps his Overweight rating and $20 price target on Aziyo Biologics following its first quarterly results as a public company. Aziyo's revenue and gross margins topped expectations and its key core business grew 31% despite facing a "difficult comparison" from the same period last year, the analyst tells investors in a research note. O'Brien further cites Aziyo's positive commentary about the benefits of the "break-through designation for Cangaroo sales into premier hospitals next year", adding that he is increasingly confident in the company's ability to deliver over 20% revenue growth going forward. | ||||
Reports Q3 revenue… Reports Q3 revenue $11.77M, consensus $11.21M. Loss per share in Q3, which includes the accretion of deemed dividends to the preferred stockholders, was $15.79 per share, compared to a loss of $4.81 per share in Q3 of 2019. "Our third quarter results reflect the strong performance of our Core Products, which showed year-over-year growth in sales over 30%," said Ron Lloyd, CEO. "Following our initial public offering in October, we are now better positioned financially and operationally to deliver on the opportunity we have in three large markets within regenerative medicine: implantable electronic devices, orthopedic and spine repair, and soft tissue reconstruction. Today, we are addressing this estimated $3 billion market with a comprehensive and growing portfolio of next-generation products driven by an expanding commercial team and partnerships with industry leaders. | ||||
Surgalign Holdings (SRGA)… Surgalign Holdings (SRGA) and Aziyo Biologics (AZYO), a commercial-stage regenerative medicine company, announced an updated distribution agreement and expanded product offering whereby Aziyo will provide ViBone(R) Moldable to Surgalign for distribution in the U.S. ViBone Moldable joins Surgalign's orthobiologic solutions to support spinal fusion, which currently include ViBone and other advanced bone graft solutions. | ||||
Truist analyst Kaila Krum… Truist analyst Kaila Krum initiated coverage of Aziyo Biologics with a Buy rating and $20 price target. The company's portfolio of core products is based on its "proprietary tissue processing platform", which addresses a range of end markets with value above $3B, the analyst tells investors in a research note. Krum adds that Aziyo's investment in commercialization, clinical development, and new product launches should lead to "strong normalized growth" as well as an expanding margin profile. | ||||